Exozymes completed a firm commitment underwritten equity offering led by MDB Capital, selling units priced at $18.00, each consisting of two shares and one warrant. The company initially issued 592,270 shares and 296,135 warrants, and MDB later exercised a portion of the over-allotment for 34,440 additional units, bringing total gross proceeds to approximately $5.95 million. Exozymes also executed a Warrant Agent Agreement with VStock Transfer to administer investor warrants and entered into an Underwriter’s Warrant Agreement providing warrants to the underwriter. Proceeds will support development and commercialization of N-trans-caffeoyltyramine (NCT), additional product opportunities, R&D, and working capital.

Agreement 1: Exozymes Enters Underwriting Agreement for $5.95 Million Equity Offering With MDB Capital

• Agreement type: Underwriting agreement for firm commitment equity offering (units of two shares and one warrant)
• Counterparty: MDB Capital
• Signed / Effective: Jun 05 2026 / Jun 05 2026
• Duration / Termination: At will
• Reason: Raise capital to fund development, R&D, and operations

Agreement 2: Exozymes Appoints VStock Transfer as Warrant Agent for Equity Offering

• Agreement type: Warrant Agent Agreement covering investor warrants from public offering
• Counterparty: VStock Transfer
• Signed / Effective: Jun 05 2026 / Jun 05 2026
• Duration / Termination: At will
• Reason: Administer and service public offering warrants

Agreement 3: Exozymes Issues Underwriter Warrants in Connection With MDB-Led Offering

• Agreement type: Underwriter’s Warrant Agreement
• Counterparty: MDB Capital
• Signed / Effective: Jun 09 2026 / Jun 09 2026
• Duration / Termination: At will
• Reason: Provide customary underwriter compensation for the offering

Original SEC Filing: EXOZYMES INC. [ EXOZ ] - 8-K - Jun. 17, 2026